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A B S T R A C T
Objective: The associations between viruses and the cancer have been conducted in several studies while there
has been no systematic review and meta-analysis about the association between viral infections and thyroid
cancer (TC). Therefore, we investigated the association between viral infection and TC risk.
Methods: Systematic search was done from 1994 to 2019 in Web of sciences (ISI), PubMed, and Scopus data-
bases. Pooled logarithm of odds ratio (OR) and their corresponding 95 % confidence interval (CI) and pooled
prevalence of viral infections were calculated to find the association between the viral infections and TC risk and
overall prevalence of the viral infections in TC.
Results: Twenty-three of 852 original articles were selected and included in the study. According to the results of
the random effect meta-analysis, the pooled prevalence of viral infections in the TC patients was 37 % (95 % C.
I= 22 %–55 %). In addition, there was a significant association between viral infections (log (OR)= 1.51, 95 %
credible interval= 0.68–2.39) and TC risk. The highest associations were observed between TC risk and Simian
Vacuolating Virus 40 (SV40) and B19 infections, respectively. The lowest non-significant association was found
between TC risk and Poliovirus type 1 infection. The significantly heterogeneity was observed between included
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studies (Q test: p-value< 0.001; I2= 73.82 %; τ2 =1.08, 95 % Cr. I= 0.47–1.94).
Conclusions: Results clearly demonstrated the potential pathogenetic association between viral infections and
increased risk of TC.
1. Introduction
Mainly, thyroid tumors as the most common endocrine malignancy
are dividing into three common histologic subtypes including differ-
entiated, medullary, and anaplastic [1]. The differentiated thyroid
cancer (DTC) itself is comprised of four sub-classes including papillary,
follicular, Hürthle and poorly differentiated which the first and second
subtypes have the highest prevalence with 80 % and 10 %, respectively
[1–3]. There are a number of factors which could be engaged in the
progression of these tumors including the changes in tumor micro-
environments and the ionizing radiation [4]. The worldwide and local
prevalence statistics of Thyroid Cancer (TC) prevalence in 2018 is in-
cluding 567,233 newly diagnosed case, lead to 41,071 death reported
[5,6]. Surveillance, The highest prevalence is observed in the patients
aged 32–65 and significantly, the higher incidence in the female is
observing [7,8]. Briefly, TC is a prevalent cancer that its incidence rate
is grown during recent years [9].
Start and progress of TC are depended on different factors such as
genetic factors, epigenetic factors and infectious agents. Major genetic
alterations that influencing in the TC are entitled in the following: 1)
Gene mutation in BRAF, RAS, etc. 2) Changing in gene amplification/
gene copy number in epidermal growth factor receptor (EGFR), vas-
cular endothelial growth factor receptor 1 (VEGFR1), etc. 3) Gene
translocation in RET-PTC and etc. and 4) Aberrant gene methylation as
an epigenetic sign of TC. Until today, multiple signaling pathways in-
volved in TC detected [10,11].
Among different infectious agents, viral infection is an important
factor involved in the tumor pathogenesis. Since 1882 that tobacco
mosaic virus discovered and subsequently discovering of yellow fever
virus in 1901 until now, scientists are trying to understand any possible
correlation between the viral infection and human diseases especially
cancer [12]. Discovering the association between Epstein–Barr virus
(EBV) and Burkitt lymphoma (BL) was one of the first approved succeed
in this way [13]. Chronic viral infection are responsible for 20–25 % of
all human cancers [14].
Nowadays the association between Epstein–Barr viruses (EBV)
[8,15,16], Human parvovirus B19 (B19) [17,18], BK virus (BKV) [19],
Human Herpes Simplex Virus (HSV) [20], and Hepatitis C Virus (HCV)
[21–23] and TC investigated and confirmed by numerous studies. These
viruses deploy their impacts on the initiation and progression of TC by
one or many of above-mentioned molecular alterations. For instance,
EBV intervenes in TC by affecting on the BRAF gene, metastases sup-
pressor Mn23 gene, and NF-κB signaling pathway [24–26].
The systematic reviews designing to detect the missing of evidence
in a scientific field and determining the aspects that should be studied
in the future because of the insufficient data. The systematic reviews
can be included the meta-analysis or not [27]. We previously perform a
systematic review to determine the impact of human papillomavirus
(HPV) infection in prostate cancer (PC) and our findings clearly support
the potential pathogenetic connection between HPV infection and in-
creased risk of PC [28]. Considering the achievements of previous
systematic review experience and as there is a lack of consensus be-
tween different points of view, this empirical Bayesian meta-analysis
was done to assess the possible association between infection with viral
agents and the risk of TC.
2. Methodology
2.1. Search strategies
A systematic search was conducted using ISI Web of Science,
PubMed and Scopus to identify related and available articles (until
August 2019). Searches were done by using the following keywords:
“Thyroid Cancer”, “Thyroid Tumor/Tomour”, “Infection” and “Viral
Infection”, alone or combined together with the Boolean operators
“OR”, “AND” and “NOT” in the Title/Abstract/Keywords field.
Unpublished studies were not included and duplicate ones were re-
moved. The search was done by three reviewers independently and
separately. Then the search results were compared to avoid missing any
article. References of collected papers were also checked for relevant
articles. We also searched other sources such as greylit.org, open-
grey.eu, scholar.google.com and researchgate.net. In order to increase
of specificity in the search results, the titles, abstracts and keywords
field of all papers were scanned and irrelevant studies were excluded.
2.2. Inclusion and exclusion criteria
A protocol for the inclusion and exclusion of eligible peer-reviewed
publications was defined that performed the following criteria.
Inclusion criteria: (A) The studies published 1994–2019, (B) The studies
reporting the presence of viral infections in TC patients, (C) All Studies
included samples from Tissue and Serum. Exclusion criteria: (I) Studies
with incomplete data or failed presented data clearly, (III) Animal
models based researches, (IV) Researches that have bacterial infections
/other infectious agents, (V) Studies with overlapping subjects, time,
and place of sample collection, (VI) Case report articles, congress ab-
stracts, meta-analysis or systematic reviews and studies reported in
languages other than English.
2.3. Data extraction and quality assessment
Two authors separately extracted the data, including author’s name,
year of publication, patient and control number, country, types of
viruses, type of sample, type of detection methods and type of tumor.
Individual data from each included study were used in this meta-ana-
lysis. Extracted data were compared and rechecked by the first and
corresponding authors. The quality of the included studies was assessed
using the Newcastle-Ottawa Scale (NOS). According to this scale, stu-
dies were classified as low (scores 0–3), moderate (scores 4–6) and high
(scores 7–9) qualities [29]. NOS score for all of the included studies was
more than 5 (range: 6–9).
2.4. Statistical methods
First, we used the Freeman-Tukey Double arcsine transformation of
relative frequencies to calculate a pooled proportion as an effect size of
viral infection prevalence in TC [30]. A random effect model derived
the pooled prevalence of the viruses in the cancer patients, while the I2
index is more than to 50 % and p-value of Cochran’s Q test less than
0.05, otherwise this pooled prevalence was derived by a fixed effect
model. Next, pooled log odds ratio (OR) and corresponding 95 %
credible interval as an effect size of the association of virus’s infection
and TC risk using empirical Bayesian meta-analysis. The Bayesian meta-
analysis is an alternative to the classical analysis for measuring accurate
pooled effect size especially in situations with a small number of studies
[31,32]. In Bayesian meta-analysis, any information about the
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unknown parameters has been specified in the analysis as prior in-
formation. In addition, in meta-analysis, heterogeneity among the effect
size measures is common because of variation in study characteristics
[32,33]. To estimate the unknown variance of the prior distribution in a
Bayesian model, Morris introduced a variance estimator it can use as
the empirical Bayes estimator in some meta-analysis applications
[33–35]. In this empirical Bayes meta-analysis, supposes that logarithm
of the OR follows a normal distribution θ τ( , )2 . The mean of the normal
distribution, θ, has a low informative normal distribution (mean=
0.525, SD=100) and the variance of the normal distribution, τ2, has
an inverse‐gamma distribution (2.0001, 1.38). The hyper-parameters in
the low informative normal distribution and the inverse-gamma dis-
tribution were estimated by classical meta-analysis based on the in-
cluded studies. Cochran’s Q test was used to test heterogeneity, τ2 and I2
indices was employed for calculating the total variation in the pooled
estimations [36]. Forest plot displayed Log (OR) and 95 % credible
interval for both the individual study and for the pooled effect size from
this meta‐analysis. In addition, heterogeneity plot displayed joint pos-
terior density of the two parameters of the Bayesian meta‐analysis
model, Log (OR), and τ parameters. Publication bias was checked by
Egger’s linear regression test and Begg’s test [37]. All statistical ana-
lyses were conducted by using “bayesmeta” and “metafor" R packages.
3. Results
3.1. Characteristics of the included studies
Twenty-three studies were included in the final meta-analysis. The
selected studies were included 1475 cases and 874 healthy subjects.
Among all studies, 52.1 % (12/23) were conducted in Asian people as
the most studied of all continents. Publication year of these studies was
ranged from 1994 to 2019. The most common method of diagnosis was
Polymerase chain reaction (PCR).
A total of 852 articles were retrieved by searching of the mentioned
database. In a primary screening process, 95 of the publications were
excluded due to duplication. Results of the secondary screening process
were the exclusion of 702 publications based on the title and abstract
evaluation, and 55 articles were retained for detailed full-text evalua-
tion. Finally, 23 articles were included. Articles met our inclusion cri-
teria and were considered in this meta-analysis (Fig. 1). The key char-
acteristics of included studies are presented in Tables 1.
3.1.1. Prevalence of the viral infections in TC
Based on 23 included studies, 552 patients from 1475 TC patients
had viral infections. According to the results of the random effect meta-
analysis, the pooled prevalence of viral infections in the TC patients was
37 % (95 % C. I= 22 %–55 %). The heterogeneity of prevalence be-
tween studies was observed (Q test: p-value<0.001; I2= 96.3 %;
τ2 =2.94). The highest and lowest prevalence of viral infections was
observed in the TC patients related to B19 and HCV, respectively. Forest
plot for the pooled prevalence was shown in Fig. 2.
3.2. Association between viral infections and TC risk
According to the results of empirical Bayesian meta-analysis based
on 12 case-control studies, there was significant association between
viral infections (log (OR)=1.51, 95 % credible interval= 0.68–2.39)
and TC risk. In other words, presence of viral infections significantly
increased the risk of TC (Fig. 3). The highest associations were observed
between TC risk and Simian Vacuolating Virus 40 (SV40) and B19 in-
fections, respectively. The lowest non-significant association was found
between TC risk and Poliovirus type 1 infection. The heterogeneity of
Fig. 1. PRISMA Flow diagram for selection of publication.
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log (OR) between studies was observed (Q test: p-value<0.001;
I2= 73.82 %; τ2 =1.08, 95 % Cr. I= 0.47–1.94). (Fig. 4).
3.3. Publication bias and sensitivity analysis
Publication bias was evaluated by Egger’s and Begg’s tests.
Publication bias was not statistically significant in the meta-analysis
(Begg’s p-value=0.39, Egger’s p-value= 0.14). Furthermore, the ro-
bustness of Bayesian analysis was confirmed by several sensitivity
analyses. Sensitivity analyses with different choices of low‐information
prior distributions indicated robustness of these choices.
4. Discussion
The discovery of new prognostic biomarkers is a significant unmet
clinical need in the treatment of various cancers. This need is under-
lined by the increased TC rates worldwide [5]. In recent years, several
factors involved in Biological carcinogens, such as viral infections [54].
Tumorigenesis and development of TC have been discovered and bio-
logical carcinogens, such as viral infections is one of the most important
factor [8,14,17].
Very few studies, especially meta-analyses, have investigated the
association between the viral infections and risk of TC. In a study, EBV
infection was detected in 71.9 % of TC tissue as a risk factor for this
cancer (OR=1.631; 95 % CI= 0.537–4.947). The results pf this study
demonstrated EBV infection may involve in the development of TC [8].
In the current meta-analysis, the pooled prevalence of viral infections in
the TC patients was 37 % (95 % CI=22 %–55 %) and the risk of viral
infection was (OR=1.51; 95 % CI= 0.68–2.39) (Fig. 2,3). Also, we
showed that the highest and lowest prevalence of viral infections was
observed in the TC patients related to B19 and HCV, respectively
(Fig. 2). Another important point of the current study was the highest
associations were observed between TC risk and Simian Vacuolating
Virus 40 (SV40) and B19 infections, respectively (Fig. 3). Etemadi et al.
determined the presence of B19 and association between its proteins
with increased inflammation in TC development. Their results indicated
86.11 % (31/ 36) of B19 DNA prevalence. They demonstrated a sig-
nificant positive correlation between presences of parvovirus B19 and
its protein and risk of thyroid tumor. Also, they showed the high level of
Non- structural protein 1 (NS1), NF-κB, tumor necrosis factor-alpha
(TNF-α), interleukin-6 (IL-6), and reactive oxygen nitrogen species
(RONS) in all TC samples [17]. NS1 of B19 lead to expression of IL-6
and TNF-α through the NF-κB-binding site in the IL-6 promoter [55,56].
The role of IL-6 in the immunological microenvironment of TC and
enhancement effect of B19 infection on IL-6 expression was shown by
Al-Gharrawi research group [57]. In another investigation, 25 % of B19
infection and high level of interferon gamma (IFN-γ), IL-6, TNF-α has
been shown [56].
Fig. 2. Forest plot displaying the prevalence of viral infections in the TC pa-
tients.
Fig. 3. Forest plot displaying log (OR) and corresponding 95 % credible interval as an effect size of the association between viral infections and TC risk.
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Ozdarendeli et al. detected SV40 in 66 % of papillary and 100 % of
anaplastic thyroid carcinomas, respectively [41]. SV40 is involved in
tumor development in different ways and one of them is activates
vascular endothelial growth factor expression through T antigen (T Ag)
[58]. For determination of association between SV40 infection and TC
development additional researches are required.
Another important viral oncogene is EBV. This virus has a role in
tumor development through prevention of anoikis (a form of pro-
grammed cell death) [59]. Moghoofei et al. evaluated the association
between EBV infection and TC. Their results showed the expression
levels of inflammatory factors such as including IL‐1, IL‐6, TNF-α and
INF-α/β were higher in the EBV‐positive tumor tissues than the EBV‐-
negative tissues. Also, they reported a positive correlation between EBV
and its proteins with anoikis resistance. This research demonstrated
that the presence of the EBV and its gene expression was associated
with thyroid tumor development [8]. Among thyroid tumor types, pa-
pillary was most associated with viral infections [8,17,60]. This is
probably because papillary type is the most common type of TC with
approximately 80 percent of cases [61–63].
This meta-analysis is suffered some limitations. First, because of the
insufficient original data, we could not perform a subgroup analysis
based on the type of viral infections. Second, heterogeneity observed
between included studies due to variations in demographic specifica-
tions among the studies, geographic factors, different viral infections,
and differences in the inclusion criteria for the study populations.
Despite significant results in the classical meta-analysis, the number of
included studies was not considerably large, and thus the results should
be interpreted with caution. In the Bayesian meta-analysis, the credible
interval is slightly wider than that of classical meta-analysis and the
results tend to be more consistent [32].The viruses are involved in
cancer development through the diverse biological pathways. Viral
proteins have important role in this process, therefore the viral proteins
and non-coding RNAs in precancerous and cancer tissues can be at-
tractive targets for novel cancer therapies and as preventive. For ex-
ample, Lamuvidine and Ganciclovir (antiviral drugs) target the viral
replication machinery in HBV and Kaposi sarcoma virus [64].
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